Neuroprotective effect of Fn14 deficiency is associated with induction of the granulocyte-colony stimulating factor (G-CSF) pathway in experimental stroke and enhanced by a pathogenic human antiphospholipid antibody

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 1-9

  Frauenknecht, Katrin ^a   Bargiotas, Panagiotis ^b   Bauer, Henrike ^a   von Landenberg, Philipp ^a   Schwaninger, Markus ^b   Sommer, Clemens ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Fn14; Granulocyte colony stimulating factor; Neuroprotection; Stroke

Indexed keywords

ADAPTOR PROTEIN; CYTOKINE TWEAK; GLIAL FIBRILLARY ACIDIC PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; MICROTUBULE ASSOCIATED PROTEIN 2; PHOSPHOLIPID ANTIBODY; RECEPTOR FN14; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; AUTACOID; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL ACTIVATION; CELL DENSITY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; HEMISPHERE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY; MOUSE; NEUROPIL; NEUROPROTECTION; NONHUMAN; POSTERIOR COMMUNICATING ARTERY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; STROKE; TRANSGENIC MOUSE; WHITE MATTER; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; DEFICIENCY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RANDOM ALLOCATION; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 77956651450     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.05.043     Document Type: Article

References (59)

1. Barone F.C., Knudsen D.J., Nelson A.H., Feuerstein G.Z., Willette R.N. Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. J. Cereb. Blood Flow Metab. 1993, 13:683-892.
2. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., Kittner S.J. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001, 32:1701-1706.
3. Brey R.L., Chapman J., Levine S.R., Ruiz-Irastorza G., Derksen R.H., Khamashta M., Shoenfeld Y. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003, 12:508-513.
4. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16.
5. Cabiedes J., Cabral A.R., Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J. Rheumatol. 1995, 22:1899-1906.
6. Cervera R., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Kiss E., Zeher M.M., Tincani A., Kontopoulou-Griva I., Galeazzi M., Bellisai F., Meroni P.L., Derksen R.H., de Groot P.G., Gromnica-Ihle E., Baleva M., Mosca M., Bombardieri S., Houssiau F., Gris J.C., Quéré I., Hachulla E., Vasconcelos C., Roch B., Fernández-Nebro A., Piette J.C., Espinosa G., Bucciarelli S., Pisoni C.N., Bertolaccini M.L., Boffa M.C., Hughes G.R. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2009, 68:1428-1432. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).
7. Chapman J., Cohen-Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
8. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y.M., Scott H., Hession C., Garcia I., Browning J.L. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 1997, 272:32401-32410.
9. Chicheportiche Y., Chicheportiche R., Sizing I., Thompson J., Benjamin C.B., Ambrose C., Dayer J.M. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 2002, 4:126-133.
10. Clemens N., Frauenknecht K., Katzav A., Sommer C., von Landenberg P. In vitro effects of APS-IgG fractions and of a human monoclonal antiphospholipid IgG antibody on HUVECs and monocytes-promotion of procoagulant activity and inflammation. Ann. N. Y. Acad. Sci. 2009, 1173:805-813.
11. Connolly E.S., Winfree C.J., Springer T.A., Naka Y., Liao H., Yan S.D., Stern D.M., Solomon R.A., Gutierrez-Ramos J.C., Pinsky D.J. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996, 97:209-216.
12. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
13. Desplat-Jégo S., Varriale S., Creidy R., Terra R., Bernard D., Khrestchatisky M., Izui S., Chicheportiche Y., Boucraut J. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J. Neuroimmunol. 2002, 133:116-123.
14. Diederich K., Sevimli S., Dörr H., Kösters E., Hoppen M., Lewejohann L., Klocke R., Minnerup J., Knecht S., Nikol S., Sachser N., Schneider A., Gorji A., Sommer C., Schäbitz W.R. The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice. J Neurosci 2009, 29:11572-11581.
15. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22:391-397.
16. Döring Y., Hurst J., Lorenz M., Prinz N., Clemens N., Drechsler M.D., Bauer S., Chapman J., Shoenfeld Y., Blank M., Lackner K.J., von Landenberg P. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010, 215:230-241.
17. A receptors in the rat brain. Brain Res. 2009, 1271:95-102.
18. Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H., Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2002, 299:488-493.
19. Horstman L.L., Jy W., Bidot C.J., Ahn Y.S., Kelley R.E., Zivadinov R., Maghzi A.H., Etemadifar M., Mousavi S.A., Minagar A. Antiphospholipid antibodies: paradigm in transition. J. Neuroinflammation 2009, 6:3.
20. Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., von Landenberg P. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683-691.
21. Inta I., Frauenknecht K., Dörr H., Kohlhof P., Rabsilber T., Auffarth G.U., Burkly L., Mittelbronn M., Hahm K., Sommer C., Schwaninger M. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J. Neurol. Sci. 2008, 275:117-120.
22. Jakubowski A., Ambrose C., Parr M., Lincecum J.M., Wang M.Z., Zheng T.S., Browning B., Michaelson J.S., Baetscher M., Wang B., Bissell D.M., Burkly L.C. TWEAK induces liver progenitor cell proliferation. J. Clin. Invest. 2005, 115:2330-2340.
23. Kadhim H.J., Duchateau J., Sébire G. Cytokines and brain injury: invited review. J. Intensive Care Med. 2008, 23:236-249.
24. Katzav, A., Faust-Socher, A., Kvapil, F., Michaelson, D.M., Blank, M., Pick, C.G., Shoenfeld, Y., Korczyn, A.D., Chapman, J. (in press) Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.02.007.
25. Khamashta M.A., Harris E.N., Gharavi A.E., Derue G., Gil A., Vázquez J.J., Hughes G.R. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann. Rheum. Dis. 1988, 47:849-854.
26. Kim S.H., Kang Y.J., Kim W.J., Woo D.K., Lee Y., Kim D.I., Park Y.B., Kwon B.S., Park J.E., Lee W.H. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ. J. 2004, 68:396-399.
27. Kitagawa K., Matsumoto M., Yang G., Mabuchi T., Yagita Y., Hori M., Yanagihara T. Cerebral ischemia after bilateral carotid artery occlusion and intraluminal suture occlusion in mice: evaluation of the patency of the posterior communicating artery. J. Cereb. Blood Flow Metab. 1998, 18:570-579.
28. Kleinschnitz C., Schwab N., Kraft P., Hagedorn I., Dreykluft A., Schwarz T., Austinat M., Nieswandt B., Wiendl H., Stoll G. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 2010, 115:3835-3842.
29. Krause I., Leibovici L., Blank M., Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007, 16:176-180.
30. Kriz J., Lalancette-Hébert M. Inflammation, plasticity and real-time imaging after cerebral ischemia. Acta Neuropathol. 2009, 117:497-509.
31. Majid A., He Y.Y., Gidday J.M., Kaplan S.S., Gonzales E.R., Park T.S., Fenstermacher J.D., Wei L., Choi D.W., Hsu C.Y. Differences in vulnerability to permanent focal cerebral ischemia among 3 common mouse strains. Stroke 2000, 31:2707-2714.
32. Matesic D.F., Lin R.C. Microtubule-associated protein 2 as an early indicator of ischemia-induced neurodegeneration in the gerbil forebrain. J. Neurochem. 1994, 63:1012-1020.
33. Menachem A., Chapman J., Katzav A. Hyperactivity induced by antiphospholipid syndrome serum. Ann. N. Y. Acad. Sci. 2009, 1173:422-436.
34. Minnerup J., Heidrich J., Wellmann J., Rogalewski A., Schneider A., Schäbitz W.R. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 2008, 39:1855-1861.
35. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., Groot PG D.E., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on the update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4:295-306.
36. Pham M., Helluy X., Braeuninger S., Jakob P., Stoll G., Kleinschnitz C., Bendszus M. Outcome of experimental stroke in C57Bl/6 and Sv/129 mice assessed by multimodal ultra-high field MRI. Exp. Transl. Stroke Med. 2010, 2:6.
37. Polavarapu R., Gongora M.C., Winkles J.A., Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear Factor-κB pathway activation. J. Neurosci. 2005, 25:10094-100100.
38. Polek T.C., Talpaz M., Darnay B.G., Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J. Biol. Chem. 2003, 278:32317-32323.
39. Popp A., Jaenisch N., Witte O.W., Frahm C. Identification of ischemic regions in a rat model of stroke. PLoS ONE 2009, 4:e4764.
40. Potrovita I., Zhang W., Burkly L., Hahm K., Lincecum J., Wang M.Z., Maurer M.H., Rossner M., Schneider A., Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J. Neurosci. 2004, 24:8237-8244.
41. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
42. Roubey R.A., Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997, 350:1491-1493.
43. Saas P., Boucraut J., Walker P.R., Quiquerez A.L., Billot M., Desplat-Jego S., Chicheportiche Y., Dietrich P.Y. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 2000, 32:102-107.
44. Saidi S., Mahjoub T., Almawi W.Y. Lupus anticoagulants and antiphospholipid antibodies as risk factors for a first episode of ischemic stroke. J. Thromb. Haemost. 2009, 7:1075-1080.
45. Schneider A., Krüger C., Steigleder T., Weber D., Pitzer C., Laage R., Aronowski J., Maurer M.H., Gassler N., Mier W., Hasselblatt M., Kollmar R., Schwab S., Sommer C., Bach A., Kuhn H.G., Schäbitz W.R. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Invest. 2005, 115:2083-2098.
46. Serafini B., Magliozzi R., Rosicarelli B., Reynolds R., Zheng T.S., Aloisi F. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J. Neuropathol. Exp. Neurol. 2008, 67:1137-1148.
47. Shah N.M., Khamashta M.A., Atsumi T., Hughes G.R. Outcome of patients with anticardiolipin antibodies: a 10year follow-up of 52 patients. Lupus 1998, 7:3-6.
48. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., Pick C.G., Leider-Trejo L., Kalashnikova L., Blank M., Chapman J. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
49. Shoenfeld Y., Twig G., Katz U., Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J. Autoimmun. 2008, 30:74-83.
50. Simantov R., LaSala J.M., Lo S.K., Gharavi A.E., Sammaritano L.R., Salmon J.E., Silverstein R.L. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest. 1995, 96:2211-2219.
51. Tanne D., Katzav A., Beilin O., Grigoriadis N.C., Blank M., Pick C.G., Landenberg P., Shoenfeld Y., Chapman J. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol. Dis. 2008, 30:56-64.
52. Vega-Ostertag M.E., Ferrara D.E., Romay-Penabad Z., Liu X., Taylor W.R., Colden-Stanfield M., Pierangeli S.S. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J. Thromb. Haemost. 2007, 5:1828-1834.
53. von Landenberg C., Lackner K.J., von Landenberg P., Lang B., Schmitz G. Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J. Autoimmun. 1999, 13:215-223.
54. Wiley S.R., Winkles J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003, 14:241-249.
55. Winkles J.A. The Tweak-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008, 7:411-425.
56. Xu H., Okamoto A., Ichikawa J., Ando T., Tasaka K., Masuyama K., Ogawa H., Yagita H., Okumura K., Nakao A. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem. Biophys. Res. Commun. 2004, 318:422-427.
57. Yepes M., Brown S.A., Moore E.G., Smith E.P., Lawrence D.A., Winkles J.A. A Soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol. 2005, 166:511-520.
58. Zhang X., Winkles J.A., Gongora M.C., Polavarapu R., Michaelson J.S., Hahm K., Burkly L., Friedman M., Li X.J., Yepes M. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J. Cereb. Blood Flow Metab. 2007, 27:534-544.
59. Zheng T.S., Burkly L.C. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J. Leukoc. Biol. 2008, 84:338-47.